Radiation recall with anticancer agents.
Radiation recall with anticancer agents.
复制标题
DOI：
10.1634/theoncologist.2009-0090
复制
发表时间：
2010
期刊：
影响因子：
--
通讯作者：
Hurtig J
中科院分区：
文献类型：
--
作者：
Burris HA 3rd;Hurtig J
关于辐射回忆，还有很多需要了解的地方，目前还不可能预测哪些患者会受到影响，以及他们会对哪些药物产生反应。此外，没有明确定义的药物特征会导致放射性回忆，因此，在放疗后使用任何药物（包括新药类别）时必须牢记这一可能性。虽然目前还不可能设计治疗方案来消除放射回忆的风险，但似乎可以通过延长完成放疗和开始全剂量化疗之间的间隔来最大限度地降低风险。放射性回忆是一种急性炎症反应，局限于先前照射的区域，可在放疗后给予化疗药物时触发。它仍然是一个知之甚少的现象，但提高认识可能有助于早期诊断和适当的管理。用于治疗癌症的各种药物都与辐射回忆有关。由于大多数数据来自病例报告，因此无法确定真实发生率，但迄今为止，最常报告放射回忆反应的化疗药物包括蒽环类多柔比星、紫杉烷类多西他赛和紫杉醇以及抗代谢药吉西他滨和卡培他滨。放射性召回对任何个体患者都是药物特异性的;不可能预测哪些患者会对哪些药物产生反应，并且再激发不会均匀地诱导反应。没有可识别的导致辐射回忆的药物特征，因此，在放疗后使用任何药物（包括新药类别）时必须牢记这一可能性。虽然目前还不可能设计治疗方案来消除放射回忆的风险，但似乎可以通过延长完成放疗和开始化疗之间的间隔来最大限度地降低风险。
There is still much that needs to be understood about radiation recall, and it is not currently possible to predict which patients will be affected and to which drugs they will react. Furthermore, there are no clearly defined characteristics of drugs that cause radiation recall, and thus, it is a possibility that must be kept in mind with use of any drug after radiotherapy, including those from new drug classes. Although it is not yet possible to design treatment regimens to eliminate the risk of radiation recall, it seems likely that risks can be minimized by prolonging the interval between completion of radiotherapy and initiation of full-dose chemotherapy. Radiation recall is an acute inflammatory reaction confined to previously irradiated areas that can be triggered when chemotherapy agents are administered after radiotherapy. It remains a poorly understood phenomenon, but increased awareness may aid early diagnosis and appropriate management. A diverse range of drugs used in the treatment of cancer has been associated with radiation recall. As most data come from case reports, it is not possible to determine the true incidence, but to date the antineoplastic drugs for which radiation recall reactions have been most commonly reported include the anthracycline doxorubicin, the taxanes docetaxel and paclitaxel, and the antimetabolites gemcitabine and capecitabine. Radiation recall is drug-specific for any individual patient; it is not possible to predict which patients will react to which drugs, and rechallenge does not uniformly induce a reaction. There are no identifiable characteristics of drugs that cause radiation recall, and thus, it is a possibility that must be kept in mind with use of any drug after radiotherapy, including those from new drug classes. Although it is not yet possible to design treatment regimens to eliminate the risk of radiation recall, it seems likely that risks can be minimized by prolonging the interval between completion of radiotherapy and initiation of chemotherapy.
登录
查看更多内容
影响因子：
50.5
作者：
Castellano, D;Hitt, R;Colomer, R
通讯作者：
Colomer, R
影响因子：
--
作者：
Bar-Sela, G;Beny, A;Kuten, A
通讯作者：
Kuten, A
DOI：
10.1002/hed.10352
发表时间：
2004-02-01
影响因子：
2.9
作者：
Culp, LR;Pou, AM;Sanguineti, G
通讯作者：
Sanguineti, G
影响因子：
1.1
作者：
Borroni, G;Vassallo, C;Franchini, P
通讯作者：
Franchini, P
影响因子：
3.1
作者：
Boström, Å;Sjölin-Forsberg, G;Bergh, J
通讯作者：
Bergh, J